2022
DOI: 10.1097/md.0000000000030958
|View full text |Cite
|
Sign up to set email alerts
|

Successful treatment of Talaromyces marneffei pneumonia in a HIV-negative renal transplantation recipient: A case report

Abstract: Rationale: Talaromyces marneffei causes life-threatening opportunistic fungal infections in immunocompromised patients. It often has a poorer prognosis in non-human immunodeficiency virus (HIV)-infected than in HIV-infected individuals because of delayed diagnosis and improper treatment.Patient concerns: A 51-year-old man presented with complaints of pyrexia, cough, and expectoration that had lasted for 15 day. This patient has been taking anti-rejection medication since kidney transplant in 2011.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(9 citation statements)
references
References 12 publications
0
9
0
Order By: Relevance
“…The median time to presentation was 12 months after SOT (range, 0.5–140 months). The majority of transplant recipients were on MMF (17 of 22 [77.3%]) [ 4 , 189–191 , 215–218 , 222–225 , 227 , 229 , 230 ]. A history of acute (2) [ 190 , 215 ] or chronic (1) rejection [ 189 ] was seen in few patients.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…The median time to presentation was 12 months after SOT (range, 0.5–140 months). The majority of transplant recipients were on MMF (17 of 22 [77.3%]) [ 4 , 189–191 , 215–218 , 222–225 , 227 , 229 , 230 ]. A history of acute (2) [ 190 , 215 ] or chronic (1) rejection [ 189 ] was seen in few patients.…”
Section: Resultsmentioning
confidence: 99%
“…The majority of transplant recipients were on MMF (17 of 22 [77.3%]) [ 4 , 189–191 , 215–218 , 222–225 , 227 , 229 , 230 ]. A history of acute (2) [ 190 , 215 ] or chronic (1) rejection [ 189 ] was seen in few patients. The majority presented with fever (15 of 24 [62.5%]) [ 4 , 189 , 191–193 , 214–218 , 222 , 225 , 227 , 229 ] and disseminated disease (19 of 25 [76.0%]) [ 4 , 188–190 , 214–220 , 222 , 223 , 225–229 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“… 47/F Chang sha, China kidney elevated serum creatinine After diagnose of talaromycosis: Tac (1 mg bid to 0.5 mg bid); Tac dose was adjusted according to its blood concentration Voriconazole (200 mg bid); then changed to itraconazole (200 mg/day) N/A Li Y, et al [ 34 ], 2022. 51/M Jiangxi, China kidney coughing, fever After admission: MMF (750 mg qd, 1000 mg qn to 250 mg bid); Tac dose was adjusted according to its blood concentration Voriconazole (200 mg bid) Cured Cai DH, et al [ 35 ], 2022. 61/M Guangxi, China kidney coughing, fever and expectoration After admission: Glucocorticoids were stopped; Tac was adjusted according to its blood concentration Voriconazole (200 mg bid) N/A Xing S, et al [ 36 ], 2022.…”
Section: Discussion and Literature Reviewmentioning
confidence: 99%
“…Among the two T. marneffei -infected kidney transplant cases, including our case, patients started using fluconazole or amphotericin B approximately 12 days after admission, and they all experienced gastrointestinal bleeding [ 30 ]. On the other hand, other renal transplant patients who had timely confirmed T. marneffei infection through mNGS after admission and started taking medications within 5 days did not show significant gastrointestinal symptoms, and the treatment process went relatively smoothly [ 35 37 ]. Hence, early mNGS or other molecular biology tests (such as Mp1p assessment) should be conducted on transplant patients with unexplained fever, cough, rash, abdominal pain, and diarrhea, and prophylactic medication should be implemented to prevent disease deterioration and improve prognosis.…”
Section: Discussion and Literature Reviewmentioning
confidence: 99%